



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

31 October 2019

Rights Commence Trading

MELBOURNE – Imagion Biosystems Limited (ASX: IBX) (the **Company**), is pleased to confirm that the rights associated with the Company's Renounceable Rights Issue announced on 28 October 2019 have commenced trading on a deferred basis under the ASX ticker IBXR.

Under the Rights Issue timetable the rights trading will end on 8 November 2019.

Further Information:

Email the Company at: corpsecretary@imagionbio.com

- ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Buchan
ImagionBiosystems@we-buchan.com
+61-3-9866-4722